Author: Cheryl Stratos
-
Melanoma Drug Pipeline Update 2012
Melanoma comprises just 5% of all skin cancers but it is the most deadly. High unmet needs still persist for this tumor type and despite three decades of extensive R&D, five-year survival of advanced patients remains below 20%.There are today 242 companies plus partners developing 273 drugs targeting melanoma in development. In addition, there are…
-
Inflammation Induces Melanoma’s ‘Invisibility’ to T-cell Immunotherapy
(ChemotherapyAdvisor) – Inflammation can trigger reversible losses of antigens from melanoma cell surfaces, cloaking tumors from T-cell detection, report authors of a study published in the journal Nature. The finding might help explain melanoma resistance and relapse after initially-effective immunotherapy, the authors reported. “Adaptive cell transfer therapies (ACTs) using cytotoxic T-cells that target melanocytic antigens…
-
Targeted Therapy: Its Status and Promise in Selected Solid Tumors Part I: Areas of Major Impact
ABSTRACT: “Targeted therapy” is becoming the centerpiece of current therapeutic strategies, and is often mentioned as the desirable direction for future progress. Why and how it is replacing past approaches in the management of solid tumors is the subject of this two-part overview. Here, in Part I, we describe areas where major inroads were initially…
-
Practical Approaches to Metastatic Melanoma in the Molecular Era
Every year more than 53,000 people in the United States are diagnosed with melanoma, making it the fastest growing cancer both in the United States and worldwide, especially among young adults between the ages of 20 and 30 years. While melanoma is treatable when detected in the early stages, it causes almost 8,000 deaths annually.…
-
InteRNA Gets Nod for US Patent, Plans IND for miRNA Melanoma Drug in Late 2013
Doug Macron is the editor of GenomeWeb’s Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail him here or follow his GenomeWeb Twitter account at @Genesilencing.
-
Dabrafenib Shows Efficancy in Metastatic Melanoma
A summary of the phase III BREAK-3 trial comparing the BRAF inhibitor dabrafenib with the chemotherapy agent dacarbazine (DTIC). Patients taking dabrafenib had an improved progression-free survival (PFS) of 2.4 months compared with patients receiving chemotherapy. Read more…
-
Doctors to Watch
Antoni Ribas UCLA melanoma – Dr. Ribas is a physician-scientist conducting laboratory and clinical research focused in malignant melanoma. His research includes: laboratory and clinical translational research in adoptive cell transfer therapy with T-cell receptor (TCR) engineered lymphocytes understanding the antitumor activity of CTLA4-blocking antibodies molecular imaging and advanced immune monitoring for the study of…
-
Hospitals To Consider
MD Anderson Melanoma – The Ben Love/El Paso Corporation Melanoma and Skin Center is committed to fighting every type and stage of skin cancer. MD Anderson’s goal is to give each patient personalized care that provides the most advanced treatment with the least impact on the body for: Melanoma of the skin (ie, cutaneous melanoma)…
-
Associations and Foundations
Melanoma Research Alliance (MRA) MRA is the largest private funder of melanoma research. To date, MRA has awarded more than $38 million to 96 research programs to make transforming advances in the prevention, diagnosis and staging, and treatment of melanoma, including research in biological causes of carcinogenesis, skin screening, biomarkers, imaging, immunotherapy, molecularly targeted therapy,…